![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1620407 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of MAP4K5 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | multiple interactions | ISO | RGD:1620407 | 6480464 | Folic Acid inhibits the reaction [1, 2-Dimethylhydrazine results in decreased expression of MAP4K5 mRNA] | CTD | PMID:22206623 | 17beta-estradiol | increases expression | ISO | RGD:1620407 | 6480464 | Estradiol results in increased expression of MAP4K5 mRNA | CTD | PMID:30077407 | 17beta-estradiol | increases expression | ISO | RGD:1346481 | 6480464 | Estradiol results in increased expression of MAP4K5 mRNA | CTD | PMID:31614463 | 17beta-estradiol | multiple interactions | ISO | RGD:1620407 | 6480464 | [Polyphenols co-treated with Estradiol] results in increased expression of MAP4K5 mRNA | CTD | PMID:30077407 | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:27291303 | 2,2',4,4'-Tetrabromodiphenyl ether | affects methylation | ISO | RGD:1346481 | 6480464 | 2 more ... | CTD | PMID:32653021 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1346481 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MAP4K5 mRNA | CTD | PMID:17555868 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of MAP4K5 mRNA | CTD | PMID:21215274 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1620407 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of MAP4K5 mRNA | CTD | PMID:19933214 | 2-butoxyethanol | increases expression | ISO | RGD:1620407 | 6480464 | n-butoxyethanol results in increased expression of MAP4K5 mRNA | CTD | PMID:19812364 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1620407 | 6480464 | Fenretinide results in increased expression of MAP4K5 mRNA | CTD | PMID:28973697 | 5-fluorouracil | multiple interactions | ISO | RGD:1346481 | 6480464 | TP53 protein affects the reaction [Fluorouracil results in decreased expression of MAP4K5 mRNA] | CTD | PMID:15016801 | aflatoxin B1 | decreases methylation | ISO | RGD:1346481 | 6480464 | Aflatoxin B1 results in decreased methylation of MAP4K5 gene | CTD | PMID:27153756 | Aflatoxin B2 alpha | increases methylation | ISO | RGD:1346481 | 6480464 | aflatoxin B2 results in increased methylation of MAP4K5 intron | CTD | PMID:30157460 | all-trans-retinoic acid | decreases expression | ISO | RGD:1346481 | 6480464 | Tretinoin results in decreased expression of MAP4K5 mRNA | CTD | PMID:21934132 | all-trans-retinoic acid | increases expression | ISO | RGD:1346481 | 6480464 | Tretinoin results in increased expression of MAP4K5 mRNA | CTD | PMID:23724009 | aristolochic acid A | decreases expression | ISO | RGD:1346481 | 6480464 | aristolochic acid I results in decreased expression of MAP4K5 mRNA | CTD | PMID:33212167 | arsane | affects methylation | ISO | RGD:1346481 | 6480464 | Arsenic affects the methylation of MAP4K5 gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | RGD:1346481 | 6480464 | Arsenic affects the methylation of MAP4K5 gene | CTD | PMID:25304211 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1346481 | 6480464 | 7 more ... | CTD | PMID:20018196 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of MAP4K5 mRNA | CTD | PMID:25181051, PMID:34947998 | bisphenol A | decreases expression | ISO | RGD:1620407 | 6480464 | bisphenol A results in decreased expression of MAP4K5 mRNA | CTD | PMID:33221593 | cadmium atom | increases expression | ISO | RGD:1346481 | 6480464 | Cadmium results in increased expression of MAP4K5 mRNA | CTD | PMID:23369406 | cadmium atom | multiple interactions | ISO | RGD:1346481 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of MAP4K5 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RGD:1346481 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of MAP4K5 mRNA | CTD | PMID:35301059 | caffeine | decreases phosphorylation | ISO | RGD:1346481 | 6480464 | Caffeine results in decreased phosphorylation of MAP4K5 protein | CTD | PMID:35688186 | crocidolite asbestos | affects expression | ISO | RGD:1346481 | 6480464 | Asbestos, Crocidolite affects the expression of MAP4K5 mRNA | CTD | PMID:17331233 | cyclosporin A | increases expression | ISO | RGD:1346481 | 6480464 | Cyclosporine results in increased expression of MAP4K5 mRNA | CTD | PMID:20106945 | cyclosporin A | increases expression | ISO | RGD:1620407 | 6480464 | Cyclosporine results in increased expression of MAP4K5 mRNA | CTD | PMID:19770486 | cypermethrin | increases expression | ISO | RGD:1346481 | 6480464 | cypermethrin results in increased expression of MAP4K5 protein | CTD | PMID:36063984 | dioxygen | increases expression | ISO | RGD:1620407 | 6480464 | Oxygen deficiency results in increased expression of MAP4K5 mRNA | CTD | PMID:22629407 | dioxygen | multiple interactions | ISO | RGD:1620407 | 6480464 | Oxygen inhibits the reaction [Oxygen deficiency results in increased expression of MAP4K5 mRNA] | CTD | PMID:22629407 | disodium selenite | decreases expression | ISO | RGD:1346481 | 6480464 | Sodium Selenite results in decreased expression of MAP4K5 mRNA | CTD | PMID:18175754 | dorsomorphin | multiple interactions | ISO | RGD:1346481 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4K5 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1346481 | 6480464 | Doxorubicin results in decreased expression of MAP4K5 mRNA | CTD | PMID:29803840 | elemental selenium | multiple interactions | EXP | | 6480464 | [Selenium deficiency co-treated with Vitamin E deficiency] results in increased expression of MAP4K5 mRNA | CTD | PMID:11444866 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of MAP4K5 mRNA | CTD | PMID:29391264 | folic acid | multiple interactions | ISO | RGD:1620407 | 6480464 | Folic Acid inhibits the reaction [1, 2-Dimethylhydrazine results in decreased expression of MAP4K5 mRNA] | CTD | PMID:22206623 | geldanamycin | increases expression | ISO | RGD:1346481 | 6480464 | geldanamycin results in increased expression of MAP4K5 mRNA | CTD | PMID:26705709 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of MAP4K5 mRNA | CTD | PMID:33387578 | hydrogen cyanide | decreases expression | ISO | RGD:1620407 | 6480464 | Hydrogen Cyanide results in decreased expression of MAP4K5 mRNA | CTD | PMID:33914522 | hydroquinone O-beta-D-glucopyranoside | decreases expression | ISO | RGD:1346481 | 6480464 | Arbutin results in decreased expression of MAP4K5 mRNA | CTD | PMID:17103032 | ivermectin | decreases expression | ISO | RGD:1346481 | 6480464 | Ivermectin results in decreased expression of MAP4K5 protein | CTD | PMID:32959892 | lead diacetate | increases expression | ISO | RGD:1620407 | 6480464 | lead acetate results in increased expression of MAP4K5 mRNA | CTD | PMID:21322097 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of MAP4K5 mRNA | CTD | PMID:25729387 | paracetamol | affects expression | ISO | RGD:1620407 | 6480464 | Acetaminophen affects the expression of MAP4K5 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | ISO | RGD:1346481 | 6480464 | Acetaminophen results in increased expression of MAP4K5 mRNA | CTD | PMID:26690555 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:1620407 | 6480464 | [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of MAP4K5 mRNA | CTD | PMID:36331819 | phenobarbital | affects expression | ISO | RGD:1346481 | 6480464 | Phenobarbital affects the expression of MAP4K5 mRNA | CTD | PMID:19159669 | potassium cyanide | decreases expression | ISO | RGD:1620407 | 6480464 | Potassium Cyanide results in decreased expression of MAP4K5 mRNA | CTD | PMID:33914522 | resveratrol | multiple interactions | ISO | RGD:1346481 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of MAP4K5 mRNA | CTD | PMID:23557933 | SB 431542 | multiple interactions | ISO | RGD:1346481 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4K5 mRNA | CTD | PMID:27188386 | selenium atom | multiple interactions | EXP | | 6480464 | [Selenium deficiency co-treated with Vitamin E deficiency] results in increased expression of MAP4K5 mRNA | CTD | PMID:11444866 | sunitinib | increases expression | ISO | RGD:1346481 | 6480464 | Sunitinib results in increased expression of MAP4K5 mRNA | CTD | PMID:31533062 | tetrachloromethane | increases expression | ISO | RGD:1620407 | 6480464 | Carbon Tetrachloride results in increased expression of MAP4K5 mRNA | CTD | PMID:31919559 | thimerosal | decreases expression | ISO | RGD:1346481 | 6480464 | Thimerosal results in decreased expression of MAP4K5 mRNA | CTD | PMID:27188386 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of MAP4K5 mRNA | CTD | PMID:25729387 | topotecan | decreases expression | EXP | | 6480464 | Topotecan results in decreased expression of MAP4K5 mRNA | CTD | PMID:25729387 | trichostatin A | decreases expression | ISO | RGD:1346481 | 6480464 | trichostatin A results in decreased expression of MAP4K5 mRNA | CTD | PMID:24935251, PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1346481 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP4K5 mRNA | CTD | PMID:27188386 | troglitazone | decreases expression | ISO | RGD:1620407 | 6480464 | troglitazone results in decreased expression of MAP4K5 mRNA | CTD | PMID:28973697 | valproic acid | decreases expression | ISO | RGD:1620407 | 6480464 | Valproic Acid results in decreased expression of MAP4K5 mRNA | CTD | PMID:21427059 | valproic acid | affects expression | ISO | RGD:1346481 | 6480464 | Valproic Acid affects the expression of MAP4K5 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1346481 | 6480464 | Valproic Acid results in decreased expression of MAP4K5 mRNA | CTD | PMID:23179753, PMID:27188386 | vitamin E | multiple interactions | EXP | | 6480464 | [Selenium deficiency co-treated with Vitamin E deficiency] results in increased expression of MAP4K5 mRNA | CTD | PMID:11444866 | vorinostat | decreases expression | ISO | RGD:1346481 | 6480464 | vorinostat results in decreased expression of MAP4K5 mRNA | CTD | PMID:27188386 | |